# Pheon Therapeutics

Source: https://onco.cc/companies/pheon-therapeutics/  
OnCo record `pheon-therapeutics` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Pheon Therapeutics, of London, designs antibody-drug conjugates against an undisclosed target overexpressed across a wide range of solid tumours; its lead carries eight topoisomerase 1 inhibitor molecules per antibody and showed a wide therapeutic index preclinically. It raised a 120 million dollar Series B in 2024 and has entered early human trials.

## Summary

Pheon Therapeutics is a London-based antibody-drug conjugate specialist building a pipeline of ADCs against undisclosed new targets and clinically validated ones, using either its proprietary payload platform, which acts through a mechanism distinct from established payloads, or established linker-payloads. Its first three assets address an undisclosed novel target that is highly overexpressed across a wide range of solid tumours; the lead uses a DAR8 topoisomerase 1 inhibitor linker-payload and the company reported an unusually wide preclinical therapeutic index, with a first phase 1 trial planned from 2024. By September 2025 the company described itself as clinical-stage. In May 2024 Pheon closed a USD 120 million Series B led by TCGX with BVF Partners, Lightspeed and Perceptive Advisors alongside existing investors Atlas Venture, Brandon Capital, Forbion and Research Corporation Technologies.

## Fields

- Kind: Company
- Last checked: 2026-09-10
- HQ: London
- Type: biotech
- Website: https://pheontx.com/

## Notes

- Lead target undisclosed. Series A (2022) not fetched and omitted.

## Sources

- Official website: https://pheontx.com/
- Series B press release: https://pheontx.com/pheon-therapeutics-announces-120m-series-b-financing-to-fund-development-of-its-differentiated-adc-pipeline/

## Connected records

- fronts: [Antibody-Drug Conjugates](https://onco.cc/fronts/adcs/)
- technologies: [Antibody-drug conjugate (ADC)](https://onco.cc/technologies/adc/), [Topoisomerase-I inhibitors (and ADC payloads)](https://onco.cc/technologies/topoisomerase-inhibitors/)
- companies: [Atlas Venture](https://onco.cc/companies/atlas-venture/), [Forbion](https://onco.cc/companies/forbion/), [Lightspeed Venture Partners](https://onco.cc/companies/lightspeed-venture-partners/), [Perceptive Advisors](https://onco.cc/companies/perceptive-advisors/), [TCGX (TCG Crossover)](https://onco.cc/companies/tcgx/)

---
JSON: https://onco.cc/api/v1/entities/pheon-therapeutics.json